CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer

(2019) Shanshan Bai et al.   ONCOGENE

Breast Cancer Treatment

(2019) Adrienne G. Waks et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer

(2019) Jinglu Wang et al.   FASEB JOURNAL

Hepatocellular Carcinoma

(2019) Augusto Villanueva   NEW ENGLAND JOURNAL OF MEDICINE

Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma

(2019) Taylor Hashiguchi et al.   MOLECULAR CANCER THERAPEUTICS

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer

(2019) Devon R. Blake et al.   Science Signaling

Targeting CDK9 for treatment of colorectal cancer

(2019) Muhammed H. Rahaman et al.   Molecular Oncology

AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells.

(2019) Justin Cidado et al.   CLINICAL CANCER RESEARCH

Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer

(2019) Xin Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy

(2019) Heyu Song et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Chronic Lymphocytic Leukemia: A Review of Front-line Treatment Options, With a Focus on Elderly CLL Patients

(2018) Alma O'Reilly et al.   Clinical Lymphoma Myeloma & Leukemia

Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation

(2018) Uri Mbonye et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MicroRNA-874 inhibits cell proliferation and invasion by targeting cyclin‑dependent kinase 9 in osteosarcoma

(2018) Wei Tang et al.   Oncology Letters

The HIV-1 Tat protein recruits a ubiquitin ligase to reorganize the 7SK snRNP for transcriptional activation

(2018) Tyler B Faust et al.   eLife

Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer

(2018) Joshua W. Russo et al.   CANCER LETTERS

Cyclin-dependent kinase 9 as a potential specific molecular target in NK cell leukemia/lymphoma

(2018) Shiori Kinoshita et al.   HAEMATOLOGICA

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia

(2018) Muhammed H. Rahaman et al.   INVESTIGATIONAL NEW DRUGS

Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity.

(2018) Jennifer Robinson Diamond et al.   JOURNAL OF CLINICAL ONCOLOGY

A Cdk9–PP1 switch regulates the elongation–termination transition of RNA polymerase II

(2018) Pabitra K. Parua et al.   NATURE

Positive Regulation of Transcription by Human ZMYND8 through Its Association with P-TEFb Complex

(2018) Koushik Ghosh et al.   Cell Reports

Cyclin‐dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway

(2018) Junfen Xu et al.   IUBMB LIFE

Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer

(2018) Daphne Brisard et al.   Oncotarget

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma

(2018) Hangzhan Ma et al.   EBioMedicine

CDK9: A key player in cancer and other diseases

(2017) Lia Carolina Franco et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

(2017) Calla M Olson et al.   Nature Chemical Biology

Paused RNA polymerase II inhibits new transcriptional initiation

(2017) Wanqing Shao et al.   NATURE GENETICS

The code and beyond: transcription regulation by the RNA polymerase II carboxy-terminal domain

(2017) Kevin M. Harlen et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

SIRT7-dependent deacetylation of CDK9 activates RNA polymerase II transcription

(2017) Maximilian F. Blank et al.   NUCLEIC ACIDS RESEARCH

Inhibitors of cyclin-dependent kinases as cancer therapeutics

(2017) Steven R. Whittaker et al.   PHARMACOLOGY & THERAPEUTICS

CDK9 is a prognostic marker and therapeutic target in pancreatic cancer

(2017) Anna-Laura Kretz et al.   TUMOR BIOLOGY

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma

(2017) Johannes Brägelmann et al.   Cell Reports

CDK9-dependent RNA polymerase II pausing controls transcription initiation

(2017) Saskia Gressel et al.   eLife

miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9

(2017) Chi Pang et al.   Cancer Medicine

The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects

(2017) Lynh Nguyen et al.   Genes

Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells

(2016) Shao Xie et al.   ACTA PHARMACOLOGICA SINICA

Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)

(2016) Arne Scholz et al.   CANCER RESEARCH

P-TEFb regulation of transcription termination factor Xrn2 revealed by a chemical genetic screen for Cdk9 substrates

(2016) Miriam Sansó et al.   GENES & DEVELOPMENT

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

(2016) Yogesh A. Sonawane et al.   JOURNAL OF MEDICINAL CHEMISTRY

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

(2016) I. A. Asangani et al.   MOLECULAR CANCER RESEARCH

High-throughput discovery of novel developmental phenotypes

(2016) Mary E. Dickinson et al.   NATURE

An evolutionary conserved Hexim1 peptide binds to the Cdk9 catalytic site to inhibit P-TEFb

(2016) Lydia Kobbi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer

(2016) Sandeep Rajput et al.   Oncotarget

Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites

(2016) Robert J. Allaway et al.   Oncotarget

CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression

(2016) Partha Mitra et al.   Oncotarget

Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer

(2016) Yu Zhao et al.   Cell Reports

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity

(2016) Zhenghu Chen et al.   Scientific Reports

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia

(2015) A. Baker et al.   CANCER RESEARCH

CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer

(2015) Yubao Wang et al.   CELL

The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells

(2015) KATJA STORCH et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist

(2015) S G T Devaraj et al.   LEUKEMIA

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

(2015) J Flynn et al.   LEUKEMIA

Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia

(2015) Joshua F. Zeidner et al.   LEUKEMIA RESEARCH

Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing

(2015) Kaiwei Liang et al.   MOLECULAR AND CELLULAR BIOLOGY

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes

(2015) Clélia Laitem et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes

(2015) Clélia Laitem et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

(2015) Frédéric R. Santer et al.   Oncotarget

Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism

(2015) Huasong Lu et al.   eLife

CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo

(2015) G P Gregory et al.   LEUKEMIA

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

(2015) Elisabeth Walsby et al.   Oncotarget

Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73

(2015) Frankie Lam et al.   Oncotarget

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

(2014) S. K. Kumar et al.   BLOOD

Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor

(2014) Camilla L. Christensen et al.   CANCER CELL

CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer

(2014) Edmond Chipumuro et al.   CELL

CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells

(2014) Elif Arisan et al.   CURRENT PHARMACEUTICAL DESIGN

MicroRNA-874 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting CDK9

(2014) Ling Wang et al.   FEBS LETTERS

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma

(2014) Chun-Hao Huang et al.   GENES & DEVELOPMENT

Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia

(2014) M-P Garcia-Cuellar et al.   LEUKEMIA

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

(2014) T. Yin et al.   MOLECULAR CANCER THERAPEUTICS

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

Cyclin-dependent kinases

(2014) Marcos Malumbres   GENOME BIOLOGY

Genetic heterogeneity in breast cancer: the road to personalized medicine?

(2013) Richard D Baird et al.   BMC Medicine

Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers

(2013) Surojeet Sengupta et al.   BREAST CANCER RESEARCH AND TREATMENT

Brd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause Release

(2013) Wen Liu et al.   CELL

Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1

(2013) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

(2013) Monica M. Mita et al.   Clinical Breast Cancer

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

(2013) John J Nemunaitis et al.   Journal of Translational Medicine

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

(2013) Joe J. Stephenson et al.   LUNG CANCER

Transcription Factors Mediate the Enzymatic Disassembly of Promoter-Bound 7SK snRNP to Locally Recruit P-TEFb for Transcription Elongation

(2013) Ryan P. McNamara et al.   Cell Reports

MLL-ENL Inhibits Polycomb Repressive Complex 1 to Achieve Efficient Transformation of Hematopoietic Cells

(2013) Emanuel Maethner et al.   Cell Reports

Phosphorylation of CDK9 at Ser175 Enhances HIV Transcription and Is a Marker of Activated P-TEFb in CD4+ T Lymphocytes

(2013) Uri R. Mbonye et al.   PLoS Pathogens

The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508

(2012) Sonja Baumli et al.   ACS Chemical Biology

The Structural Basis for Control of Eukaryotic Protein Kinases

(2012) Jane A. Endicott et al.   Annual Review of Biochemistry

RNA Polymerase II Elongation Control

(2012) Qiang Zhou et al.   Annual Review of Biochemistry

Pol II CTD kinases Bur1 and Kin28 promote Spt5 CTR-independent recruitment of Paf1 complex

(2012) Hongfang Qiu et al.   EMBO JOURNAL

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

(2012) S. P. Glaser et al.   GENES & DEVELOPMENT

Androgen Receptor Serine 81 Phosphorylation Mediates Chromatin Binding and Transcriptional Activation

(2012) Shaoyong Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells

(2012) A J Johnson et al.   LEUKEMIA

Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans

(2012) Karen Adelman et al.   NATURE REVIEWS GENETICS

Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II

(2012) Stéphane Larochelle et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

CTD serine-2 plays a critical role in splicing and termination factor recruitment to RNA polymerase II in vivo

(2012) Bo Gu et al.   NUCLEIC ACIDS RESEARCH

PKC phosphorylates HEXIM1 and regulates P-TEFb activity

(2012) Koh Fujinaga et al.   NUCLEIC ACIDS RESEARCH

Estrogen receptor-α recruits P-TEFb to overcome transcriptional pausing in intron 1 of the MYB gene

(2012) Partha Mitra et al.   NUCLEIC ACIDS RESEARCH

BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain

(2012) B. N. Devaiah et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CDK2 Regulates HIV-1 Transcription by Phosphorylation of CDK9 on Serine 90

(2012) Denitra Breuer et al.   Retrovirology

Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition

(2012) Nadine Czudnochowski et al.   Nature Communications

The Pathogenesis of Mixed-Lineage Leukemia

(2011) Andrew G. Muntean et al.   Annual Review of Pathology-Mechanisms of Disease

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family

(2011) Panagis Filippakopoulos et al.   BIOORGANIC & MEDICINAL CHEMISTRY

B-cell receptor signaling in chronic lymphocytic leukemia

(2011) F. K. Stevenson et al.   BLOOD

Ubiquitination of HEXIM1 by HDM2

(2011) Joanne Lau et al.   CELL CYCLE

Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma

(2011) Christopher Abdullah et al.   CELL CYCLE

Two-pronged Binding with Bromodomain-containing Protein 4 Liberates Positive Transcription Elongation Factor b from Inactive Ribonucleoprotein Complexes

(2011) Sebastian Schröder et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The CDK inhibitors in cancer research and therapy

(2011) Jonas Cicenas et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cdk9 T-loop phosphorylation is regulated by the calcium signaling pathway

(2011) Rajesh Ramakrishnan et al.   JOURNAL OF CELLULAR PHYSIOLOGY

T-Cell Receptor Signaling Enhances Transcriptional Elongation from Latent HIV Proviruses by Activating P-TEFb through an ERK-Dependent Pathway

(2011) Young Kyeung Kim et al.   JOURNAL OF MOLECULAR BIOLOGY

Insights into the Phosphoryl Transfer Mechanism of Cyclin-Dependent Protein Kinases from ab Initio QM/MM Free-Energy Studies

(2011) Gregory K. Smith et al.   JOURNAL OF PHYSICAL CHEMISTRY B

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

(2011) K C Goh et al.   LEUKEMIA

Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription

(2011) Sonal M. Manohar et al.   LEUKEMIA RESEARCH

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

(2011) Mark A. Dawson et al.   NATURE

Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation

(2011) Rui Zhao et al.   NATURE CELL BIOLOGY

55K isoform of CDK9 associates with Ku70 and is involved in DNA repair

(2010) Hongbing Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

c-Myc Regulates Transcriptional Pause Release

(2010) Peter B. Rahl et al.   CELL

Cyclin-dependent kinase 9–cyclin K functions in the replication stress response

(2010) David S Yu et al.   EMBO REPORTS

Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom)

(2010) M. Mohan et al.   GENES & DEVELOPMENT

CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1

(2010) B. Bartkowiak et al.   GENES & DEVELOPMENT

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia

(2010) Zhifu Xiang et al.   JOURNAL OF CLINICAL INVESTIGATION

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

HIV-1 Tat and Host AFF4 Recruit Two Transcription Elongation Factors into a Bifunctional Complex for Coordinated Activation of HIV-1 Transcription

(2010) Nanhai He et al.   MOLECULAR CELL

AFF4, a Component of the ELL/P-TEFb Elongation Complex and a Shared Subunit of MLL Chimeras, Can Link Transcription Elongation to Leukemia

(2010) Chengqi Lin et al.   MOLECULAR CELL

HIV-1 Tat Assembles a Multifunctional Transcription Elongation Complex and Stably Associates with the 7SK snRNP

(2010) Bijan Sobhian et al.   MOLECULAR CELL

CDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 Phosphorylation

(2010) Vicki Gordon et al.   MOLECULAR ENDOCRINOLOGY

RNA-mediated displacement of an inhibitory snRNP complex activates transcription elongation

(2010) Iván D'Orso et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Recent developments in cyclin-dependent kinase biochemical and structural studies

(2009) Aude Echalier et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Acetylation of cyclin T1 regulates the equilibrium between active and inactive P-TEFb in cells

(2009) Sungyoo Cho et al.   EMBO JOURNAL

New insights to the MLL recombinome of acute leukemias

(2009) C Meyer et al.   LEUKEMIA

Cyclin T2 Is Essential for Mouse Embryogenesis

(2009) J. Kohoutek et al.   MOLECULAR AND CELLULAR BIOLOGY

Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription

(2009) Anup Dey et al.   MOLECULAR BIOLOGY OF THE CELL

7SK snRNP/P-TEFb couples transcription elongation with alternative splicing and is essential for vertebrate development

(2009) M. Barboric et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

(2008) C. Pepper et al.   BLOOD

The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation

(2008) Sonja Baumli et al.   EMBO JOURNAL

PP2B and PP1  cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling

(2008) R. Chen et al.   GENES & DEVELOPMENT

The Bromodomain Protein Brd4 Stimulates G1Gene Transcription and Promotes Progression to S Phase

(2008) Kazuki Mochizuki et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Positive Transcription Elongation Factor b Is an Essential Cofactor for the Activation of Transcription by Myocyte Enhancer Factor 2

(2008) Masanori Nojima et al.   JOURNAL OF MOLECULAR BIOLOGY

Bromodomain Protein Brd4 Regulates Human Immunodeficiency Virus Transcription through Phosphorylation of CDK9 at Threonine 29

(2008) M. Zhou et al.   JOURNAL OF VIROLOGY

Acetylation of Conserved Lysines in the Catalytic Core of Cyclin-Dependent Kinase 9 Inhibits Kinase Activity and Regulates Transcription

(2008) A. Sabo et al.   MOLECULAR AND CELLULAR BIOLOGY

A La-Related Protein Modulates 7SK snRNP Integrity to Suppress P-TEFb-Dependent Transcriptional Elongation and Tumorigenesis

(2008) Nanhai He et al.   MOLECULAR CELL

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology

(2008) S WANG et al.   TRENDS IN PHARMACOLOGICAL SCIENCES